Leonardo Calza1, Michele Sachs2, Vincenzo Colangeli2, Marco Borderi2, Bianca Granozzi2, Pietro Malosso2, Giorgia Comai3, Valeria Corradetti3, Gaetano La Manna3, Pierluigi Viale2. 1. Unit of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola Hospital, "Alma Mater Studiorum" University of Bologna, via G. Massarenti 11, 40138, Bologna, Italy. leonardo.calza@unibo.it. 2. Unit of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola Hospital, "Alma Mater Studiorum" University of Bologna, via G. Massarenti 11, 40138, Bologna, Italy. 3. Unit of Nephrology, Department of Medical and Surgical Sciences, S.Orsola Hospital, University of Bologna, Bologna, Italy.
Abstract
BACKGROUND: Chronic kidney disease (CKD) has become one of the most frequent non-infectious comorbidities in the aging HIV-infected population on long-standing combination antiretroviral therapy (cART). METHODS: We conducted a retrospective, cross-sectional study including HIV-infected adult patients attending our HIV outpatient clinic during the years 2017 and 2018 to assess prevalence and associated risk factors of CKD. Estimated glomerular filtration rate (eGFR) was measured by Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. CKD was diagnosed and classified according to the National Kidney Foundation guidelines. Logistic regression was employed to identify factors associated with CKD. RESULTS: We enrolled 2339 HIV-infected patients (91% were Caucasian) with a mean age of 45.3 years and a mean current CD4 lymphocyte count of 531 cells/mm3. CKD was diagnosed in 311 subjects (13.3%). Overall, 294 (12.6%) patients had albuminuria, 108 (4.6%) had eGFR < 60 mL/min/1.73 m2, and 78 (3.3%) had albuminuria plus eGFR < 60 mL/min/1.73 m2. Stages 4-5 of CKD were documented in 23 (1%) cases. Age greater than 50 years, male gender, hypertension, diabetes mellitus, high triglycerides, nadir CD4 cell count < 200 cells/mm3, current use of tenofovir disoproxyl fumarate (TDF) and of TDF plus a ritonavir-boosted protease inhibitors were independently associated with CKD, while current use of abacavir plus one integrase inhibitor was associated with a reduced risk of CKD. CONCLUSION: There is a significant prevalence of CKD among HIV-infected persons in association with both traditional and HIV-specific risk factors, requiring a careful periodic monitoring of renal function in these patients.
BACKGROUND:Chronic kidney disease (CKD) has become one of the most frequent non-infectious comorbidities in the aging HIV-infected population on long-standing combination antiretroviral therapy (cART). METHODS: We conducted a retrospective, cross-sectional study including HIV-infected adultpatients attending our HIV outpatient clinic during the years 2017 and 2018 to assess prevalence and associated risk factors of CKD. Estimated glomerular filtration rate (eGFR) was measured by Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. CKD was diagnosed and classified according to the National Kidney Foundation guidelines. Logistic regression was employed to identify factors associated with CKD. RESULTS: We enrolled 2339 HIV-infectedpatients (91% were Caucasian) with a mean age of 45.3 years and a mean current CD4 lymphocyte count of 531 cells/mm3. CKD was diagnosed in 311 subjects (13.3%). Overall, 294 (12.6%) patients had albuminuria, 108 (4.6%) had eGFR < 60 mL/min/1.73 m2, and 78 (3.3%) had albuminuria plus eGFR < 60 mL/min/1.73 m2. Stages 4-5 of CKD were documented in 23 (1%) cases. Age greater than 50 years, male gender, hypertension, diabetes mellitus, high triglycerides, nadir CD4 cell count < 200 cells/mm3, current use of tenofovir disoproxyl fumarate (TDF) and of TDF plus a ritonavir-boosted protease inhibitors were independently associated with CKD, while current use of abacavir plus one integrase inhibitor was associated with a reduced risk of CKD. CONCLUSION: There is a significant prevalence of CKD among HIV-infectedpersons in association with both traditional and HIV-specific risk factors, requiring a careful periodic monitoring of renal function in these patients.
Authors: Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech Journal: Clin Infect Dis Date: 2005-04-22 Impact factor: 9.079
Authors: Lene Ryom; Amanda Mocroft; Ole Kirk; Peter Reiss; Michael Ross; Colette Smith; Olivier Moranne; Philippe Morlat; Christoph A Fux; Caroline Sabin; Andrew Phillips; Matthew Law; Jens D Lundgren Journal: AIDS Date: 2017-06-01 Impact factor: 4.177
Authors: Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian Journal: Clin Infect Dis Date: 2014-09-17 Impact factor: 9.079
Authors: José R Arribas; Melanie Thompson; Paul E Sax; Bernhard Haas; Cheryl McDonald; David A Wohl; Edwin DeJesus; Amanda E Clarke; Susan Guo; Hui Wang; Christian Callebaut; Andrew Plummer; Andrew Cheng; Moupali Das; Scott McCallister Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Udeme E Ekrikpo; Andre P Kengne; Aminu K Bello; Emmanuel E Effa; Jean Jacques Noubiap; Babatunde L Salako; Brian L Rayner; Giuseppe Remuzzi; Ikechi G Okpechi Journal: PLoS One Date: 2018-04-16 Impact factor: 3.240
Authors: Edgar T Overton; Amy Kantor; Kathleen V Fitch; Paul Muntner; Khuanchai Supparatpinyo; Mosepele Mosepele; Lerato Mohapi; Sandra Wagner Cardoso; Sandesh Patil; Marcus V G de Lacerda; Grace McComsey; Judith A Aberg; Pamela S Douglas; Steven K Grinspoon; Heather Ribaudo; Christina M Wyatt Journal: J Infect Dis Date: 2020-07-09 Impact factor: 5.226
Authors: Herry Mapesi; James Okuma; Fabian Franzeck; Herieth Ismael Wilson; Elizabeth Senkoro; Theonestina Byakuzana; Robert Ndege; Fiona Vanobberghen; Tracy Renée Glass; Manuel Battegay; Maja Weisser; Daniel Henry Paris Journal: PLoS One Date: 2021-12-15 Impact factor: 3.240
Authors: Brian Ferrari; Amanda Cabral Da Silva; Ken H Liu; Evgeniya V Saidakova; Larisa B Korolevskaya; Konstantin V Shmagel; Carey Shive; Gabriela Pacheco Sanchez; Mauricio Retuerto; Ashish Arunkumar Sharma; Khader Ghneim; Laura Noel-Romas; Benigno Rodriguez; Mahmoud A Ghannoum; Peter P Hunt; Steven G Deeks; Adam D Burgener; Dean P Jones; Mirela A Dobre; Vincent C Marconi; Rafick-Pierre Sekaly; Souheil-Antoine Younes Journal: J Clin Invest Date: 2022-05-02 Impact factor: 19.456
Authors: Giovanni Sarteschi; Antonio Di Biagio; Emanuele Focà; Lucia Taramasso; Francesca Bovis; Anna Celotti; Michele Mirabella; Laura Magnasco; Sara Mora; Mauro Giacomini; Matteo Bassetti Journal: PLoS One Date: 2020-10-15 Impact factor: 3.240